LUPIN

September 16, 2013

The National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051.

Dear Sirs,

Sub: Disclosure pursuant to Clause 36 of the Listing Agreement.

Enclosed is a press release as regards receipt of final USFDA approval for the Company's Zolpidem Tartrate Extended-release tablets USP 6.25 mg and 12.5 mg to market a generic version of Sanofi Aventis, U.S., LLC's Ambien CR® Extended-release tablets, 6.25 mg and 12.5 mg.

The above may be considered as a disclosure pursuant to Clause 36 of the Listing Agreement.

Thanking you,

Yours faithfully,
For LUPIN LIMITED

R. V. SATAM
COMPANY SECRETARY & COMPLIANCE OFFICER

Encl.: a/a.

Press Release

LUPIN

BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO BLOOMBERG: LPC IN

Lupin Receives FDA Approval for Generic Ambien CR® Extended-release Tablets

Mumbai, Baltimore, September 16, 2013: Pharma major, Lupin Limited (Lupin), announced today that it has received final approval for its Zolpidem Tartrate Extended-release tablets USP, 6.25 mg and 12.5 mg from the United States Food and Drugs Administration (FDA) to market a generic version of Sanofi Aventis, U.S, LLC's (Sanofi) Ambien CR® Extended-release tablets, 6.25 mg and 12.5 mg. Lupin's wholly owned US subsidiary Lupin Pharmaceuticals Inc. (LPI) shall commence marketing the product shortly.

Lupin's Zolpidem CR tablets 6.25 mg & 12.5 mg is the AB rated generic equivalent of Sanofi's Ambien CR® Extended-release tablets, 6.25 mg and 12.5 mg and is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.

Sanofi's Ambien CR® Extended-release tablets had annual U.S sales of approximately US$ 366 million (IMS MAT Mar 2013).

About Lupin Limited

Headquartered in Mumbai, Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.

Lupin is the 5th largest and fastest growing generics player in the US (5.1% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales. The Company is also the fastest growing top 10 generic pharmaceutical players in Japan and South Africa (IMS).

For the financial year ended March 2012, Lupin's Consolidated Total Income and Profit after Tax were Rs. 70,972 million (USD 1.49 billion) and Rs.8,676 million (USD 182 million) respectively. Please visit http://www.lupinworld.com for more information.

Lupin Pharmaceuticals, Inc. is the wholly owned U.S. subsidiary of Lupin Limited. Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is dedicated to delivering high-quality, affordable generic medicines and branded formulations trusted by healthcare professionals and patients across geographies. For more information, visit http://www.lupinpharmaceuticals.com

For further information or queries please contact -

Shamsher Gorawara
Head – Corporate Communications
Lupin Limited
Ph: +91 98 20 338 555
Email: shamshergorawara@lupinpharma.com

or

Rajiv Pillai
Head – Investor Relations
Lupin Limited

Press Release

LUPIN

BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO BLOOMBERG: LPC IN

Ph: +91 98 20 552 083
Email: rajivpillai@lupinpharma.com

Safe Harbor Statement

** Ambien CR® is the registered trademark of Sanofi Aventis, U.S, LLC*